Annexon reports third quarter 2024 portfolio and financial results, and key anticipated milestones

Topline real-world evidence (rwe) comparability and outcomes data for anx005 in guillain-barrÉ syndrome (gbs) expected by year-end 2024; biologics license application (bla) submission targeted for first half 2025

ANNX Ratings Summary

ANNX Quant Ranking